Introduction
Hepatitis B virus (HBV) infections are prevalent in both Turkey and the rest of the world, and chronic hepatitis is the leading chronic viral disease (1, 2) . Chronic hepatitis B infections may present a wide range of manifestations from the inactive carrier state to cirrhosis and hepatocellular cancer (HCC) (3) .
The goals of treatment for CHB are to permanently suppress HBV replication and to relieve hepatic damage. The ultimate target of treatment is the prevention of cirrhosis and hepatocellular cancer (HCC) (4) (5) (6) . ALT normalization, HBV DNA clearance, HBeAg seroconversion, and improved liver histology may be seen during treatment (7, 8) .
Entecavir, which is a potent drug recommended in the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) guidelines, was first used for CHB after approval in the US in 2005 and in Turkey in 2007. It is a 2-deoxyguanosine analog, and after triple phosphorylation by the host's cellular kinases it forms entecavir phosphate (ETV-TP). Its half-life is 15 h, similar to lamivudine. ETV-TP inhibits HBV replication in 3 separate steps, which differentiates it from other nucleoside or nucleotide analogs. These steps are inhibition of HBV-DNA polymerase primers, inhibition of negative strand reverse transcription from pregenomic RNA of HBV-DNA, and inhibition of HBV-DNA positive strand synthesis. Triple-step inhibition of HBV highly suppresses HBV-DNA, and in vitro studies showed that entecavir is a stronger antiviral agent than lamivudine and adefovir (4, 6, 9) .
In our literature review, there were no other studies covering such a high number of patients in this country. In this study, the data of 199 CHB patients treated with 0.5 mg/day of entecavir for 48 weeks were retrospectively evaluated.
Materials and methods
This study retrospectively evaluated 199 treatment-naive chronic hepatitis patients who were treated with entecavir. This study was approved by the local ethics committee.
Biopsies were performed as suggested by AASLD criteria. After marking via hepatic ultrasonography, the biopsy was performed with a 16G Hepafix or Tru-cut liver biopsy needle. Samples were sent to the pathology laboratory immersed in a formaldehyde solution. Entecavir 0.5 mg/day was started in patients with chronic hepatitis B in accordance with the Turkish public health system. Patient inclusion criteria were: having no previous treatment for chronic hepatitis B; being over 18 years old; having no compensated or decompensated cirrhosis; having no contraindication for liver biopsy; and those who were not pregnant or breastfeeding.
Before treatment, patients' age, sex, address, phone number, body mass index, occupation, family history, underlying illnesses, symptoms, physical examination findings, laboratory values (thrombocyte, leukocyte, hemoglobin, prothrombin time (PT)), activated partial thromboplastin time (APTT), HBsAg, antiHBs, HBeAg, antiHBe, antiHCV, antiHDV, HBV DNA, ALT, AST, albumin, creatinine, alpha fetoprotein (AFP), radiologic findings (upper abdominal ultrasonography), pathology results (Ishak score, a modified Knodell score, from liver biopsy), and treatment protocols were recorded in patient charts. Clinical complaints, physical examination findings, and laboratory findings (HBV DNA, ALT, AST, and creatinine) during follow-up visits were also recorded on the same chart. Patients were thoroughly evaluated again at the end of week 48, and symptoms, physical examination findings, laboratory values (hemoglobin, PT, APTT, HBsAg, antiHBs, HBeAg, antiHBe, antiHCV, antiHDV, HBV DNA, ALT, AST, albumin, creatinine, phosphate, calcium, ALP, and AFP), and radiologic findings (upper abdominal ultrasonography) were also recorded in the follow-up form.
During the treatment, HBV DNA, ALT, AST, and creatinine values were measured at weeks 4, 12, 24, and 48 and were recorded in patient charts. Data were entered in the SPSS 16.0 software. Categorical data were analyzed by chi-square test, and continuous variables were analyzed by t test and Mann-Whitney U test. To analyze repeated measures, the analysis of variance of repeated measures test was used, and significant results in this test were analyzed by signed rank test. P < 0.05 was considered statistically significant.
Results
Of 199 treatment-naive chronic hepatitis B patients, 141 (70.9%) were males and 58 (29.1%) were females. The mean age of the general group was 37.5 ± 12.1. Family history was positive in 155 (77.9%) patients (Table 1) .
HBeAg was positive in 91 (45.7%) and antiHBe was positive in 108 (54.3%) patients. Mean HBV DNA value was 666,449,365.5 ± 2,759,013,996.9 IU/mL, mean ALT value was 112.1 ± 95.7 U/L, and mean AST value was 95.3 ± 71.2 U/L (Table 2) .
During follow-up visits, ALT and HBV DNA values had markedly decreased, and this decrease was statistically significant (P value 0.001 and 0.001, respectively) ( Table  3) .
In our study, HBV DNA values decreased at each follow-up visit at weeks 0, 4, 12, 24, and 48 after entecavir 0.5 mg/day, and this decrease was statistically significant (P = 0.01). The values of HBV DNA at weeks 4, 12, 24, and 48 were significantly lower than values at the treatment's start (P values were 0.01 for all) (Table 3) . Additionally, HBV DNA values at the weeks following treatment courses were significantly lower than the values at weeks before treatment courses (P values were 0.02 for all). At week 24, HBV DNA was below 50 IU/mL in 56% of HBeAgpositive and 76% of HBeAg-negative patients. At week 48 of treatment, HBV DNA was below 50 IU/mL in 79% of HBeAg-positive and 87% of HBeAg-negative patients.
ALT values decreased both in HBeAg-positive and negative patients at each follow up visit at weeks 0, 4, 12, 24, and 48 after entecavir 0.5 mg/day, and this decrease was statistically significant (P = 0.001). Values of ALT at weeks 4, 12, 24, and 48 were significantly lower than values at the start of the treatment (P values < 0.01 for all). Moreover, ALT values for the weeks following treatment courses were significantly lower than the values for the weeks before treatment courses (P values were 0.01 for all) ( Table 3) . By week 24, ALT had normalized in 72% of HBeAg-positive and 79% of HBeAg-negative patients (P = 0.310). By week 48, ALT had normalized in 89% of HBeAg-positive and 88% of HBeAg-negative patients (P = 0.818). At week 48 of treatment, mean ALT value was 28 U/L (range of 13-77). AntiHBe seroconversion was seen in 2 of 91 patients (2.2%), but loss of HBsAg was never observed.
Patients tolerated the drug well. Nausea was reported by 12 (6%), abdominal pain by 5 (2.5%), diarrhea by 5 (2.5%), and headache by 4 (2%) patients. No other side effects were observed. None of the side effects were significant enough to warrant discontinuation of the treatment.
Discussion
Virologic response in chronic hepatitis B treatment is defined as a decrease in HBV DNA to values undetectable by PCR and a loss of HBeAg in patients who were HBeAg positive at the beginning of the treatment (4). Chang et al. (10) measured HBV DNA levels below 300 copy/mL in 236 of 354 patients (67%) at week 48. Zheng et al. (11) followed 66 HBeAg-positive patients treated with entecavir 0.5 mg/ day for 24 months. Plasma HBV levels below 500 copy/mL were regarded as undetectable. HBV DNA level decreased to undetectable levels in 23 (34.8%) patients at week 12 of treatment and in 38 patients (57.6%) at week 24 of treatment. Köklü et al. (17) obtained a virologic response in 92.6% of the patients. We found that in HBeAg-positive and negative patients, with 48 weeks of entecavir 0.5 mg/ day treatment, HBV DNA levels decreased at each followup visit at weeks 0, 4, 12, 24, and 48. This decline was statistically significant. By week 24, HBV DNA levels were below 50 IU/mL in 56% of HBeAg-positive and 76% of HBeAg-negative patients. By week 48, HBV DNA levels were below 50 IU/mL in 79% of HBeAg-positive and 87% of HBeAg-negative patients. Our results were in concordance with the studies by Song et al. (12) and Zheng et al. (11) (Table 4) .
AASLD guidelines define a biochemical response as a decrease in plasma ALT to normal levels (4). Gish et al. Table 4) . The HBeAg loss/seroconversion rate was 23.5% in a multicentric study conducted by Köklü et al. (17) . However, the lack of patients with HBeAg is noteworthy. We found antiHBe seroconversion in 2 (2.2%) of 91 patients after 48 weeks of treatment with entecavir 0.5 mg/ day. The antiHBe seroconversion rates were higher in the literature (4, 10, 13) . However, there have been no reported antiHBe seroconversion rates in Turkey, except the rates published by Köklü et al. (17) . The lack of seroconversion rates in our study was related to genotype-D dominance in this country (Table 4) . Treatment was continued in 2 patients 1 year after the antiHBe seroconversion.
The ideal result of treatment is HBsAg loss, which is frequently achievable with the currently available anti-HBV agents (6). Lok and McMahon (4) found that a loss of HBsAg was detected in 2% of patients. Chang et al. (10) found HBsAg loss in 7 (2%) of 354 patients taking entecavir at week 48 of treatment. Köklü et al. (17) did not observe HBsAg loss. We did not observe HBsAg loss in any of the patients in the current study.
Entecavir use has been associated with side effects such as mild headache, upper respiratory tract infection, cough, pharyngitis, malaise, upper abdominal pain, and gastrointestinal discomfort (18) . Chang et al. (10) reported that common side effects in patients using entecavir were mild to moderate degree headache, upper respiratory tract infection, nasopharyngitis, cough, malaise, upper abdominal pain, and diarrhea. None of these side effects was seen in 306 of 354 (86%) patients. Gish et al. (16) detected fatigue in 6% and headache in 10% of patients. Zheng et al. (11) observed that patients tolerated entecavir well. They detected upper respiratory tract infection in 6 (9.1%), fatigue in 5 (7.6%), diarrhea in 2 (3%), and cough in 1 (1.5%) of 66 patients. All of these side effects were mild to moderate in severity. In our study, we also observed that patients tolerated the drug well. We detected nausea in 12 (6%), abdominal pain in 5 (2.5%), diarrhea in 5 (2.5%), and flatulence in 4 (2%) of 199 patients. We did not observe any side effects other than those mentioned. None of the side effects were serious enough to warrant discontinuation of treatment.
In conclusion, good patient compliance, few side effects, and efficiency in suppressing the infection are the advantages of entecavir. Therefore, entecavir, which is one of the most potent agents for CHB treatment, seems to be effective and safe.
